Navigation Links
New HIV vaccine approach targets desirable immune cells
Date:9/1/2011

DURHAM, N.C. Researchers at Duke University Medical Center, Beth Israel Deaconess Medical Center and Harvard Medical School have demonstrated an approach to HIV vaccine design that uses an altered form of HIV's outer coating or envelope protein.

The researchers showed that they could design HIV envelopes that could bind better to immature B cell receptors to create an enhanced immune response in an animal model. Immature B cells are the targets of vaccines, and when strongly targeted, they produce strong vaccine responses. The work of the Duke team was to improve on the ability of the HIV envelope to target immature B cells of the immune system.

"This is first step towards a new way of making vaccines against HIV: targeting immature immune cells and attempting to drive a pathway of events that rarely occur," said Barton Haynes, M.D., co-senior author and director of the national Center for HIV-AIDS Vaccine Immunology (CHAVI) laboratory and Frederic M. Hanes Professor of Medicine and Immunology at Duke University School of Medicine. "This avenue of research provides additional evidence about why some of the earlier, traditional vaccine approaches for HIV may not have been successful."

The study was published in the Sept. 1 issue of PLoS Pathogens.

Handcrafting vaccines that will stimulate different stages of the pathway toward immunity looks to be important, Haynes said. A vaccine usually uses a part of the virus (like part of its outer coating) or a harmless form of the virus to create a strong immune response against the virus.

This new work is the first time researchers have made an HIV envelope that binds better to precursor antibodies and also stimulates better immunity, compared with a natural envelope, in primates.

Hua-Xin Liao, M.D., Ph.D., a professor of medicine in the Duke Human Vaccine Institute (DHVI) and co-senior author, created the altered HIV outer coats. "Roadblocks thrown up by
'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. GeoVax Awarded $3.6 Million Grant by U.S. Government for its HIV/AIDS Vaccine Program
2. Americans Travel to Mexico for Stem Cell Stimulation Therapies and E+ Peptide Cancer Vaccine -- Treatments Not Yet Offered in U.S.
3. Scientists take a step towards developing better vaccines for bluetongue
4. SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial
5. Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage
6. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
7. New salmonella-based clean vaccines aid the fight against infectious disease
8. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
9. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
10. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
11. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 Baylor Research Institute (BRI) ... Genomics Research Institute (TGen) in Phoenix, AZ ... accelerating early detection and treatments for patients with a broad ... will lead to new clinical trials and access to technology ... gap from bench to bedside across Baylor Scott ...
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains ... therapeutic imaging within a body lumen (open space). ... a low cost, single-use disposable illumination and camera module ... 18, 2013 and the patent approval was received on ... to customize the lighting and magnification of the endoscope ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Correction Continues after Big Move - BrokerBank Securities, Inc. 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... on its flagship,suite of medication and infusion management ... and an industry-first Performance,Analytics Service that provides hospitals ... , The ... features that can help hospitals increase the security ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... in a panel,discussion at the 2008 RBC Capital Marketing Healthcare ... Rheumatology", will take,place on Wednesday, December 10, 2008 at 10:00 ... City. , To access ...
... - Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority ... patients with genotypes 2 and 3 chronic hepatitis C - ... receiving 900-mcg Albuferon had comparable rates of serious adverse events, ... peginterferon alfa-2a - , , ...
Cached Biology Technology:Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... University previously developed ion transistors for transport of both ... has now succeeded in combining both transistor types into ... electronics. An advantage of chemical circuits is ... various functions. This means that we now have new ...
... University in Sweden reveals the value of carrying two layers ... way their protective forewings actually function. These wings do not ... from the ground albeit at a cost. The ... the insect,s flying wings and body. The function of the ...
... As gardeners get busy filling tubs and borders with ... Bristol have discovered more about what makes flowers attractive to ... Society,s journal Functional Ecology , their research reveals that ... helping bees grip flowers especially when the wind gets ...
Cached Biology News:Flapping protective wings increase lift 2Blowing in the wind: How hidden flower features are crucial for bees 2
... and non-reduced forms. It does not react with ... Factor XIII is a Beta-globulin found in plasma ... is the catalytic subunit and is a dimmer ... plasma as an Alpha2Beta2 heterodimer (M.W. 320kDa); whereas ...
... DNAscope V is a fully integrated ... and image processing that deliver excellent quality ... a high quality microarray scanner that is ... for optimal background rejection and spatial resolution. ...
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ) ... NaCl, 10 mM sodium HEPES, ... pH 7.5. Recognizes the ~47 ... 2 (MAPKAPK-2) protein phosphorylated at ...
Anti-Src-Like Adaptor Protein-2 AVOID FREEZE/THAW CYCLES. Recognizes the ~25 and ~28 kDa forms SLAP-2....
Biology Products: